Propanc Biopharma, Inc. (PPCB) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Propanc Biopharma, Inc. (PPCB) closed at USD 0.34 on 2026-10-15, a change of -99 % over the past year, with a market capitalization of USD 3.36M.

Propanc Biopharma, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Propanc Biopharma, Inc. key figures

Previous close

USD 0.34 (2026-10-15)

1-year change

-99 %

Market cap

USD 3.36M

Enterprise value

USD 1.84M

P/E ratio (trailing)

-0.02

P/E ratio (forward)

n/a

EPS (trailing)

-17.62

EPS (forward)

n/a

PEG ratio

n/a

Price to book

0.12

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.21

Employees

2

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Propanc Biopharma, Inc.

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertake research activities for the POP1 Program and the University of Granada to develop a synthetic recombinant version of PRP. Propanc Biopharma, Inc. was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Propanc Biopharma, Inc. and compare it with other stocks.